BETA DRUGS H1FY27 : CONS NET PROFIT UP 43.5% AT ₹34.3 CR (YOY)

• Revenue up 29.2% at ₹263.04 Cr (YOY). • Ebitda up ~30% at ₹61 Cr (YOY); Ebitda margins 23.18% v 23.08%, gross margins 56.2% v 51.35% (YOY). • Branded oncology growth at 17% (YOY) hit by plant shutdown and platinum API supply constraints; orders moved to H2FY27. • Management guides FY27 revenue at ₹535+ Cr with Ebitda margins 23-24%. Impact: Margins held flat despite the shutdown and H2-loaded oncology orders, leaving FY27 guidance of ₹535+ Cr revenue at 23-24% Ebitda margin as the key monitorable.

Beta Drugs Limited

Open attachment

← Back to feed